Compare Davita Inc (DVA) vs Iron Mountain Inc (IRM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Iron Mountain Inc — how do they compare? Davita Inc trades at $232 (market cap $14.92B), while Iron Mountain Inc trades at $122.4 (market cap $36.49B). The key difference: Iron Mountain Inc is far larger — about 2.4× Davita Inc's market cap, and Iron Mountain Inc pays a 2.82% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | IRM | |
|---|---|---|
Market Cap | $14.92B | $36.49B |
Sector | Health | Real Estate |
52-Week High | $235.71 | $133.06 |
52-Week Low | $103.87 | $78.86 |
Enterprise Value | $27.47B | $55.63B |
Dividend Yield | — | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
Iron Mountain (IRM) trades at $122.37, up 0.72% on the day, showing strong momentum with a 30.2% gain over three months. The stock is in a bullish technical trend, supported by recent earnings beats and positive analyst sentiment. Revenue growth accelerated to $6.90 billion in 2025, though net margins remain thin at 3.76%. Recent news highlights its data center strength and a $1.5 billion debt offering to fund expansion.
Outlook is cautiously optimistic with a consensus price target of $138.67 offering 13% upside. Risks include high debt levels (debt-to-asset ratio of 79.04% in 2025) and margin pressure. The stock appeals for its growth exposure and dividend yield, but investors should weigh leverage concerns against operational momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Iron Mountain Inc
Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →
